Abstract: Objective The aim of this study was to investigate the screening of patients with hepatitis C in the real world, and the efficacy of sofosbuvir and velpatasvir in patients with hepatitis C. Methods Serum anti-HCV screening was carried out in 3966 inpatients and outpatients in our hospital between September 2017 and September 2019, and the confirmed patients with chronic hepatitis C (CHC) received sofosbuvir and velpatasvir treatment for 12 weeks. Results Among the 3966 patients screened, serum anti-HCV positive was 2.0% (80/3966), and out of the 80 patients with anti-HCV positive, 42 cases had their serum HCV RNA loads tested and 40 cases (95.2%) were positive; in the 40 patients with CHC, there were 12 cases without any obvious symptoms and signs, 18 cases had abdominal distension, fatigue and anorexia, 10 cases had vascular spider, liver disease face, liver palms, and splenomegaly; there were 35 cases having serum AST level ＞90 U/L, 4 cases having mildly elevated serum AST level and 1 case having normal serum AST level; 3 cases had mixed HBV/HCV infection; the B-mode ultrasound examination showed normal liver in 14 cases, and increased intrahepatic light spots in 26 cases; in 40 patients with CHC treated with sofosbuvir and velpatasvir, the early virologic response, rapid virologic response, the end treatment virologic response, sustained virologic response, none response and recurrence rates were 75.0%, 80.0%, 82.5%, 72.5%, 10.0% and 10.0%, respectively; serum bilirubin level in patient after 12 weeks of treatment was (30.7±4.3) μmol/L, significantly lower than [(80.4±15.6) μmol/L, P＜0.05] before treatment, and serum AST level was (72.5±18.6) U/L, significantly lower than [(247.7±110.4) U/L, P＜0.05] before treatment; serum albumin level was (49.2±11.5) g/L, significantly higher than [(35.9±9.2) g/L, P＜0.05] before treatment; the incidence of adverse reactions was 22.5% in our series. Conclusion The prevalence of hepatitis C in the real world is relatively high, and the screening of infection is of great importance. The application of sofosbuvir and velpatasvir in the treatment of patients with hepatitis C has a promising clinical efficacy, with a good serum virological response and safety.

Key words: Hepatitis C, Screening, Sofosbuvir, Velpatasvir, Virological response, Therapy